Volasertib

Volasertib

Volasertib (pronounced vo-luh-ser-tib) is a small molecule inhibitor of PLK1 (Polo-like kinase 1), a protein that is involved in the regulation of the cell cycle. It is being investigated for its potential use in the treatment of various types of cancer.

Etymology

The name "Volasertib" is derived from the Latin "vola", meaning "fly", and "sertib", a term of unknown origin. The name may be intended to suggest the drug's ability to "fly" to its target and inhibit its function.

Mechanism of Action

Volasertib works by inhibiting the activity of PLK1, a protein that plays a key role in cell division. By blocking the function of this protein, Volasertib can prevent cancer cells from dividing and growing.

Clinical Trials

Volasertib has been tested in several clinical trials for its potential use in treating various types of cancer, including leukemia, lung cancer, and ovarian cancer. The results of these trials have been promising, but further research is needed to confirm the drug's efficacy and safety.

Side Effects

Like all drugs, Volasertib can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, and fatigue. More serious side effects, such as neutropenia (a decrease in the number of white blood cells) and thrombocytopenia (a decrease in the number of platelets), have also been reported.

Related Terms

• PLK1
• Cancer
• Clinical trials
• Leukemia
• Lung cancer
• Ovarian cancer
• Nausea
• Vomiting
• Fatigue
• Neutropenia
• Thrombocytopenia

External links

• Medical encyclopedia article on Volasertib
• Wikipedia's article - Volasertib

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski